Oncotarget is a well-known peer reviewed remedial journal that is used by thousands of people both in the medical and secular sectors. It publishes research findings and statistics on all matters related to oncology, autophagy, gerotarget aging, cellular functions, immunology, microbiology and chromosome behavior. Mikhail Blagosklonny, the chief editor and operator of Oncotarget, has made access to the journal without cost to the public. Mikhail is a specialist of oncology and considered to be extremely knowledgeable in his field and well-respected by his peers. His scientific discovery and contribution of the pharmaceutical Rapamycin, has taken the medical and health industries by storm! Not only does the drug suppress cancer laden cells, but it also has been scientifically proven to be effective in cellular rejuvenation.Rapamycin is FDA cleared to act as an immunosuppressant and cancer remedy.It has also been especially useful at preventing the body from rejecting new organs after organ transplant surgeries.
Studies have determined that through the controlled administration of the drug, cellular division can be heightened or decreased. This is significant in regard to its benefits and effectiveness to treating cancer successfully, due to the fact that higher doses stop the cancer cells from dividing. Rapamycin by-products are also being used to treat kidney, breast and lung cancers. The most promising and downright thrilling research to date has shown, when tested on mice, the lifespans were increased by a whopping fifteen percent in females. In males, the lifespan increased by nine percent. Dr. Blagosklonny is also an oncology professor at the renowned Roswell Park Cancer Institute. He specializes in the field of biometrics including Hyper Function Therapy, Signal Transduction, Apoptosis, Free Radical Function and Drug Resistance.On Oncotargets website there is an incredible amount of data collected to help both doctors and patients ascertain the most relevant findings on the market. One such contribution is on the “Breakthroughs and Discoveries” tab.
One of the latest breakthroughs in science that is noted on Oncotarget is that United Kingdom oncology experts have now formulated a compound that prevents the body from becoming drug resistant and has the potential to reverse infections.This includes the Methicillin-resistant Staphylococcus Aureus bacteria. This kind of bacteria has proven to be especially resistant to antibiotics, so it tends to spread throughout the body much quicker than Staph infections. MRSA has been prevalent in hospitals and now there is hope to eliminate it altogether through the recent findings published at Oncotarget. Oncotarget releases two new medical research papers per week and has a lengthy library archive with a vast amount of scientific findings and research.Mikhail Blagosklonny has seen many remarkable scientific discoveries that are little known outside of the medical establishments and communities. Through Oncotargets determination to make these findings available, he has impacted and fostered many lives through the successful treatment of different maladies. He is nonetheless a pioneer who continues to forge ahead the cure for cancer and fight free radical cell degradation that initiates aging and causes breakdown in the body.